Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lemaitre Vascular (LMAT) Research & Development (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Research & Development for 16 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 2.35% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.1 million, a 9.65% decrease, with the full-year FY2025 number at $14.1 million, down 9.65% from a year prior.
  • Research & Development was $3.5 million for Q4 2025 at Lemaitre Vascular, up from $3.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $4.5 million in Q2 2023 to a low of $2.7 million in Q2 2021.
  • A 5-year average of $3.6 million and a median of $3.5 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 35.75% in 2021, then dropped 18.76% in 2025.
  • Lemaitre Vascular's Research & Development stood at $3.5 million in 2021, then grew by 2.81% to $3.6 million in 2022, then rose by 22.43% to $4.4 million in 2023, then fell by 16.85% to $3.6 million in 2024, then dropped by 2.35% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Research & Development are $3.5 million (Q4 2025), $3.0 million (Q3 2025), and $3.5 million (Q2 2025).